Immunic Statistics
Total Valuation
Immunic has a market cap or net worth of $218.76 million. The enterprise value is $63.99 million.
| Market Cap | 218.76M |
| Enterprise Value | 63.99M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunic has 13.62 million shares outstanding. The number of shares has increased by 156.51% in one year.
| Current Share Class | 13.62M |
| Shares Outstanding | 13.62M |
| Shares Change (YoY) | +156.51% |
| Shares Change (QoQ) | +41.07% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 43.08% |
| Float | 11.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.05 |
| Quick Ratio | 4.96 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -138.17% and return on invested capital (ROIC) is -90.51%.
| Return on Equity (ROE) | -138.17% |
| Return on Assets (ROA) | -66.80% |
| Return on Invested Capital (ROIC) | -90.51% |
| Return on Capital Employed (ROCE) | -92.16% |
| Weighted Average Cost of Capital (WACC) | 11.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 95 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.66% in the last 52 weeks. The beta is 1.40, so Immunic's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | +93.66% |
| 50-Day Moving Average | 14.42 |
| 200-Day Moving Average | 10.42 |
| Relative Strength Index (RSI) | 62.75 |
| Average Volume (20 Days) | 156,182 |
Short Selling Information
The latest short interest is 1.43 million, so 10.53% of the outstanding shares have been sold short.
| Short Interest | 1.43M |
| Short Previous Month | 1.41M |
| Short % of Shares Out | 10.53% |
| Short % of Float | 12.29% |
| Short Ratio (days to cover) | 9.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -117.88M |
| Pretax Income | -111.57M |
| Net Income | -111.57M |
| EBITDA | -117.73M |
| EBIT | -117.88M |
| Earnings Per Share (EPS) | -$4.00 |
Balance Sheet
The company has $155.10 million in cash and $328,000 in debt, with a net cash position of $154.77 million or $11.36 per share.
| Cash & Cash Equivalents | 155.10M |
| Total Debt | 328,000 |
| Net Cash | 154.77M |
| Net Cash Per Share | $11.36 |
| Equity (Book Value) | 127.58M |
| Book Value Per Share | 9.35 |
| Working Capital | 126.57M |
Cash Flow
In the last 12 months, operating cash flow was -$87.72 million and capital expenditures -$329,000, giving a free cash flow of -$88.05 million.
| Operating Cash Flow | -87.72M |
| Capital Expenditures | -329,000 |
| Depreciation & Amortization | 149,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -88.05M |
| FCF Per Share | -$6.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -156.51% |
| Shareholder Yield | -156.51% |
| Earnings Yield | -51.00% |
| FCF Yield | -40.25% |
Analyst Forecast
The average price target for Immunic is $41.90, which is 160.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.90 |
| Price Target Difference | 160.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 27, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |